This UK stock looks pretty cheap to me

This Fool is always on the hunt for value, and with plenty of potential for growth, this UK stock ticks a lot of boxes. Let’s take a closer look.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I’m always scanning the UK stock market for value, and occasionally find that the largest companies in the market are trading for far less than expected. I recently took a closer look at pharmaceutical giant AstraZeneca (LSE: AZN), a FTSE 100 heavyweight.

Created with Highcharts 11.4.3AstraZeneca Plc PriceZoom1M3M6MYTD1Y5Y10YALL1 Sep 201930 Sep 2024Zoom ▾Jan '20Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '24Jul '242020202020212021202220222023202320242024www.fool.co.uk

In a tough period

The shares are experiencing the most significant weekly decline since July 2023. This is primarily due to disappointing results from a late-stage trial of an experimental lung cancer drug developed in partnership with Daiichi Sankyo. This setback has prompted some analysts to downgrade the stock to ‘sell’.

However, smart investors know it’s crucial to look beyond short-term volatility and consider the broader financial picture and long-term prospects. The company’s latest financial report reveals annual revenue of £37.45bn and earnings of £4.91bn. Particularly noteworthy is the firm’s impressive gross margin of 82.62%, which demonstrates the company’s ability to maintain impressive profits in a competitive industry.

Should you invest £1,000 in AstraZeneca right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if AstraZeneca made the list?

See the 6 stocks

To me though, the valuation is the most interesting part. According to a discounted cash flow (DCF) calculation, the shares are trading at approximately 51% below estimated fair value. This significant discount suggests that the market may be undervaluing the company, possibly due to an overreaction to recent news. Such an estimate can be more of an art than a science though, and it’s possible that the market is simply reflecting a lot of uncertainty.

So of course, it’s important to acknowledge the risks. The company carries a substantial debt load. There are also numerous challenges on the horizon, including the impending US patent expiry of its blockbuster drug Farxiga and pricing pressures in the Chinese market. These factors undoubtedly contribute to the current negative feeling surrounding the shares.

Reasons for optimism

Under the leadership of CEO Pascal Soriot, the company has successfully transformed itself into a leader in oncology and rare diseases. Moreover, the firm boasts a robust pipeline of potential blockbuster drugs that could drive future growth and help offset current setbacks.

The growth prospects are particularly noteworthy. Analysts forecast earnings growth of 16% per year, a figure that outpaces many peers and the broader market average. This trajectory suggests that the company is pretty well-positioned to navigate the current challenges and emerge stronger.

The shares offer a dividend yield of 1.9%. Obviously this is far from the highest yield in the FTSE 100. However, the company’s conservative payout ratio of 71% indicates plenty of room for future dividend growth as earnings expand.

One for the future

So while AstraZeneca is certainly facing a few problems, the current share price may represent an attractive opportunity for long-term investors. The company’s strong fundamentals, diverse product portfolio, and promising pipeline suggest that it’s well-equipped to weather its current storm.

The pharmaceutical industry is known for its volatility, and even well-established companies like AstraZeneca are not immune to the occasional setback. However, as an investor with a long-term perspective and a tolerance for some near-term uncertainty, I’m treating the current situation as an opportunity hiding in plain sight, and will be buying the shares at the next opportunity.

Should you invest £1,000 in AstraZeneca right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.

And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if AstraZeneca made the list?

See the 6 stocks

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Gordon Best has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Like buying £1 for 51p

This seems ridiculous, but we almost never see shares looking this cheap. Yet this recent ‘Best Buy Now’ has a price/book ratio of 0.51. In plain English, this means that investors effectively get in on a business that holds £1 of assets for every 51p they invest!

Of course, this is the stock market where money is always at risk — these valuations can change and there are no guarantees. But some risks are a LOT more interesting than others, and at The Motley Fool we believe this company is amongst them.

What’s more, it currently boasts a stellar dividend yield of around 8.5%, and right now it’s possible for investors to jump aboard at near-historic lows. Want to get the name for yourself?

See the full investment case

More on Investing Articles

artificial intelligence investing algorithms
Investing Articles

Up 272% in just a year, is Palantir stock just getting started?

This writer recognises that Palantir has grown its business very well -- but does the stock price offer him an…

Read more »

Runner standing at the starting point with 2025 year for starting in new year 2025 to achieve business planing and success concept.
Investing Articles

Up 50%? The Aston Martin share price forecast is mind-blowing! 

If analysts are right, the Aston Aston Martin share price could absolutely rocket in the year ahead. Harvey Jones says…

Read more »

Investing Articles

As the S&P 500 drops, here are 2 Stocks and Shares ISA holdings I’m watching

Our writer has different views on how President Trump's tariffs might affect these two US holdings in his Stocks and…

Read more »

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

£10,000 invested in Tesla stock at Christmas is now worth…

Tesla stock has been one of best-performing investments of the past decade. But things haven't gone to plan for investors…

Read more »

Investing Articles

Up 279% in 5 years, could Meta stock keep soaring?

Meta stock has more than tripled in five years. This writer sees lots to like about the business but also…

Read more »

Pink 3D image of the numbers '2025' growing in size
Investing Articles

25% total return in a year? Is now the perfect time to buy BP shares?

BP shares are on the front line of today's global economic and political uncertainty but analysts think they can still…

Read more »

Affectionate Asian senior mother and daughter using smartphone together at home, smiling joyfully
Investing Articles

With Cash ISA changes coming, could now be the time to consider buying shares?

Changes to the Cash ISA could lead to greater investment in the stock market. This could be a good thing…

Read more »

Investing Articles

These FTSE 100 dividend shares just got cheaper, thanks to President Trump!

Investors buying dividend shares can lock in bigger long-term yields when share prices take a tumble. These two just did…

Read more »